Last reviewed · How we verify
LAT010
At a glance
| Generic name | LAT010 |
|---|---|
| Sponsor | Latticon Antibody Therapeutics, Inc |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LAT010 CI brief — competitive landscape report
- LAT010 updates RSS · CI watch RSS
- Latticon Antibody Therapeutics, Inc portfolio CI